Revolutionizing Immuno-oncology

In late 2016, industry veteran Pete Smith joined Myrio as CEO, and the team set their sights on developing therapeutic antibodies. Recognizing that ReD is best differentiated by its ability to hit difficult targets, Myrio focused on discovering antibodies specific for pMHCs – thereby enabling cells to be targeted on the basis of their expression of particular intracellular and secreted proteins. Initial screens proved highly successful and Myrio has since gone on to successfully identify high affinity and selective antibodies against numerous pMHCs, possibly more than the rest of the world combined.

Myrio is collaborating with some of the world’s leading institutions, working on a diverse range of targets, including endogenous retroviruses and patient-specific neoantigens. These collaborations have demonstrated the utility of Myrio’s human scFv in bispecific and CAR-T formats. Myrio’s strategy is to work with partners to develop therapeutics against specific targets while also establishing spin-outs or joint-ventures to clinically develop specific assets.